Actinium Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
Actinium Pharmaceuticals, Inc. announced its Q2 2026 financial results, highlighting a substantial increase in net income driven by the recognition of $35 million in deferred revenue from a prior licensing agreement.
AMEX
Actinium Pharmaceuticals reports reduced net loss in Q3 2025, driven by cost cuts, but faces significant cash burn, Iomab-B regulatory setbacks, and ongoing legal challenges.
AMEX
Actinium Pharmaceuticals reports increased net loss for H1 2025, a strategic pivot to solid tumor therapies, and ongoing legal challenges.
AMEX
Actinium Pharmaceuticals reports its Q1 2025 financial results and provides an update on its clinical development programs, including Actimab-A, Iomab-ACT, and ATNM-400.
AMEX
10-Q: Actinium Pharmaceuticals Reports Third Quarter 2024 Results, Provides Update on Clinical Programs
Actinium Pharmaceuticals' Q3 2024 report details financial results and provides updates on the clinical development of Iomab-B, Actimab-A, and Iomab-ACT, including regulatory feedback and strategic partnership efforts.
AMEX
10-Q: Actinium Pharmaceuticals Reports Q2 2024 Results, Provides Update on Iomab-B Regulatory Pathway
Actinium Pharmaceuticals reported its second quarter 2024 financial results and provided an update on the regulatory pathway for its lead drug candidate, Iomab-B, noting the FDA requires an additional clinical trial.
AMEX
Actinium Pharmaceuticals reported a net loss of $8.7 million for the first quarter of 2024, while progressing regulatory filings for Iomab-B and advancing its pipeline.